This notion was first described in sorafenib-induced ferroptosis in hepatocellular carcinoma cells identifying metallothionein 1 G (MT1G) as a new NFE2L2-target gene responsible for ferroptosis resistance (Sun et al., 2016a,b). This evidence concerns the gene MT1G and hepatocellular carcinoma.